APA (7th ed.) Citation

Yu, J., Xiao, B., Li, D., Jiang, W., Ding, Y., Wu, X., . . . Ding, P. (2024). Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): A single-arm, open-label, phase 2 study. Lancet Oncology, 25(7), 843. https://doi.org/10.1016/S1470-2045(24)00203-1

Chicago Style (17th ed.) Citation

Yu, Jie-Hai, et al. "Neoadjuvant Camrelizumab Plus Apatinib for Locally Advanced Microsatellite Instability-high or Mismatch Repair-deficient Colorectal Cancer (NEOCAP): A Single-arm, Open-label, Phase 2 Study." Lancet Oncology 25, no. 7 (2024): 843. https://doi.org/10.1016/S1470-2045(24)00203-1.

MLA (9th ed.) Citation

Yu, Jie-Hai, et al. "Neoadjuvant Camrelizumab Plus Apatinib for Locally Advanced Microsatellite Instability-high or Mismatch Repair-deficient Colorectal Cancer (NEOCAP): A Single-arm, Open-label, Phase 2 Study." Lancet Oncology, vol. 25, no. 7, 2024, p. 843, https://doi.org/10.1016/S1470-2045(24)00203-1.